Pharmaceuticals
New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...
2022-08-01 21:00
2502
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...
2022-08-01 21:00
3207
Eccogene Announces US IND Approval for THRβ agonist ECC4703
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...
2022-08-01 15:00
2530
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:22
2251
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:17
2279
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...
2022-07-29 20:00
3763
QT MEDICAL'S Online Order, Mail Delivery, XPRESS ECG Testing Service, to Exhibit at the World's Largest Annual Trade Show
Enabling patients to conduct electrocardiogram (ECG) tests safely and efficiently at home using PCA 500, the only medical grade 12-lead Resting ECG approved by the FDA for patient use. LAS VEGAS, July 29, 2022 /PRNewswire/ -- Demand for telehealth and home care has surged drastically during the ...
2022-07-29 12:22
2841
Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever
- Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in operating revenue in the second quarter due to the growth of ethical drugs and Nabota. - A continuous increase in profitability is expected due to sales visualization of the new drug Fexuclue and Na...
2022-07-28 21:00
3604
The Clinician and Clalit Health Services partner to drive value-based care and digital care pathway implementation in Israel
AUCKLAND, New Zealand and TEL AVIV, Israel, July 28, 2022 /PRNewswire/ -- The
Clinician
2022-07-28 12:33
3025
Plant-Oil-Based Skincare Technology Business Available for License or Purchase
A NEW AND UNIQUE ANHYDROUS SKINCARE TECHNOLOGY OF PROVEN VERY HIGH EFFICACY AUCKLAND, New Zealand, July 27, 2022 /PRNewswire/ -- Invented and developed by the CEO ofFutecNZ Limited in New Zealand, (trading under the ONE24 brand) trialled and tested by accredited scientific laboratories, a vast t...
2022-07-28 05:22
2279
Samsung Biologics Reports Second Quarter 2022 Financial Results
* Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed onApril 20, 2022 * Achieved record-high semi-annual revenue exceeding KRW 1 trillion * Recorded Q2'22 revenue of KRW 503.7 billion for the company's CDMO business * Recorded ...
2022-07-27 14:43
2827
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre
* All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported * The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all H...
2022-07-26 17:04
3225
Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program
SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022
/PRNewswire/ --Ascentage Pharma
2022-07-25 21:59
3175
Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA
HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...
2022-07-25 18:47
2819
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...
2022-07-22 07:59
3115
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities
SHENZHEN, China, July 20, 2022 /PRNewswire/ -- ImmVira's global first intravenous ("IV") administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1x106 to 1x108 PFU on 10 subjec...
2022-07-21 08:00
2367
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN12088 * First-in-class new drug to quickly take on the pulmonary fibrosis market, predicted to reach$6.1 billion globally by 2030 SEOUL, South Korea, July 20, 2022 /PRNewswire/ -- As many Korean p...
2022-07-20 21:00
2334
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 19, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01...
2022-07-20 00:15
2627
Gracell Biotechnologies Appoints Veteran BioPharma Executive Dr. Samuel Zhang as Chief Business Officer
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...
2022-07-19 20:00
2517
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...
2022-07-18 20:00
2170
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 260 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9459
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9058
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8596
